Kiyotoshi Imai

Nelarabine‐combined chemotherapy improves outcome of T‐cell acute lymphoblastic leukemia but shows more severe neurotoxicity: JALSG T‐ ALL213 ‐O

Fumihiko Hayakawa, Naoki Mori, Kiyotoshi Imai, Yasuhisa Yokoyama et autres

We investigated the effectiveness and safety of nelarabine (NEL)-combined chemotherapy for newly diagnosed adult T-cell acute lymphoblastic leukemia (T-ALL) patients. We conducted a phase II trial, T-ALL213-O, where adult T-ALL patients aged 25 to 64 were treated by a regimen based on …

jp (code pays fourni par la source)

Decision Analysis for Unrelated Bone Marrow Transplantation or Immediate Cord Blood Transplantation for Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Complete Remission

Shinichi Kako, Fumihiko Hayakawa, Koichi Miyamura, Junji Tanaka et autres

An HLA-matched relative is the first-choice donor for patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1). The most promising alternative donor is thought to be an HLA-matched unrelated donor (MUD) in patients who do not have …

jp (code pays fourni par la source)

Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapy

Shinichi Kako, Fumihiko Hayakawa, Kiyotoshi Imai, Junji Tanaka et autres

jp (code pays fourni par la source)

Impact of the combination of donor age and HLA disparity on the outcomes of unrelated bone marrow transplantation

Sachiko Seo, Yoshiaki Usui, Keitaro Matsuo, Yoshiko Atsuta et autres

jp, fr (code pays fourni par la source)

Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group

Takeshi Saito, Yoshihiro Hatta, Fumihiko Hayakawa, Tsutomu Takahashi et autres

jp (code pays fourni par la source)

The Optimal Treatment Strategy for Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Complete Remission in the Era of High-Intensity Chemotherapy

Shinichi Kako, Fumihiko Hayakawa, Kiyotoshi Imai, Junji Tanaka et autres

[Background] We previously demonstrated that allogeneic hematopoietic stem cell transplantation (HSCT) in the first complete remission (CR1) was recommended for adult patients wih Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) who have a human leukocyte antigen (HLA)-matched related (Leukemia 2011;25:259-265) or unrelated …

jp (code pays fourni par la source)

Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia : AHokkaido Leukemia Net Study

Daisuke Hidaka, Masahiro Onozawa, Junichi Hashiguchi, Naohiro Miyashita et autres

jp (code pays fourni par la source)

Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study

Naomi Kawashima, Akimi Akashi, Yasunobu Nagata, Rika Kihara et autres

jp, us (code pays fourni par la source)

Prognostic Analysis According to the 2017 ELN Risk Stratification by Genetics in Adult Acute Myeloid Leukemia Patients Treated in The Japan Adult Leukemia Study Group (JALSG) AML201 study

Yasuhiko Harada, Yasunobu Nagata, Rika Kihara, Yuichi Ishikawa et autres

jp, us (code pays fourni par la source)

Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study

Daisuke Hidaka, Masahiro Onozawa, Junichi Hashiguchi, Naohiro Miyashita et autres

jp (code pays fourni par la source)

Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study

Yasuhiko Harada, Yasunobu Nagata, Rika Kihara, Yuichi Ishikawa et autres

jp, us (code pays fourni par la source)

Molecular Signatures That Predict Response to Azacitidine Treatment for Myelodysplastic Syndromes

Yasuhito Nannya, June Takeda, Shinya Sato, Yusuke Shiozawa et autres

Abstract DNA hypomethylating agents (HMAs) constitute standard therapy for higher-risk myelodysplastic syndromes (MDS). However, the lack of reliable genetic markers predicting response to HMAs precludes an optimal use of these agents. Recently, several groups have reported marked efficacy of decitabine for TP53 …

jp (code pays fourni par la source)